The mRNA stability of NCAPG2, a novel contributor to breast invasive carcinoma, is enhanced by the RNA-binding protein PCBP2.


Journal

Cellular signalling
ISSN: 1873-3913
Titre abrégé: Cell Signal
Pays: England
ID NLM: 8904683

Informations de publication

Date de publication:
10 2023
Historique:
received: 24 05 2023
revised: 18 07 2023
accepted: 03 08 2023
medline: 28 8 2023
pubmed: 7 8 2023
entrez: 6 8 2023
Statut: ppublish

Résumé

Non-SMC condensin II complex subunit G2 (NCAPG2) is one of the three non-SMC subunits in condensin II, which plays a vital role in regulating chromosome condensation and segregation. Although the tumor-promoting role of NCAPG2 has been reported in several solid malignancies, its function in breast invasive carcinoma (BRCA) remains unknown. Data both from GEPIA and GSE36295 indicated that NCAPG2 mRNA expression was abnormally upregulated in cancer tissues, which was further verified in 40 paired BRCA and para-carcinoma samples. Kaplan-Meier Plotter further illustrated that BRCA patients with higher NCAPG2 expression have a poorer prognosis. Functional experiments carried out in two BRCA cell lines (MCF-7 and T-47D) showed that NCAPG2-silenced BRCA cells acquired less aggressive behavior - weakened growth and metastasis both in vitro and in vivo. Label-free proteomics quantified the protein expression patterns in MCF-7 cells, and the results revealed 684 differentially expressed proteins (|log

Identifiants

pubmed: 37544634
pii: S0898-6568(23)00258-9
doi: 10.1016/j.cellsig.2023.110844
pii:
doi:

Substances chimiques

RNA-Binding Proteins 0
RNA, Messenger 0
PCBP2 protein, human 0
NCAPG2 protein, human 0
Chromosomal Proteins, Non-Histone 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110844

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no competing interests.

Auteurs

Sijia Han (S)

Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.

Xueying Jin (X)

Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.

Tianyu Hu (T)

Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.

Feng Chi (F)

Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. Electronic address: chif@sj-hospital.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH